Posted by Michael Wonder on 17 May 2018
FDA approves Aimovig (erenumab-aooe), a novel treatment developed specifically for migraine prevention
17 May 2018 - Aimovig is the first and only FDA approved treatment to block the calcitonin gene-related peptide receptor, which plays an important role in migraine.
Amgen today announced that the U.S. FDA has approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R) – which is believed to play a critical role in migraine.
Aimovig 70 mg is self-administered once monthly via Amgen's device, the SureClick auto-injector, and does not require a loading dose. Some patients may benefit from a dosage of 140 mg once monthly.
